Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a...
NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a...
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused...
LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on...
Clinical testing of LP-410 expected to commence in Q2 2024PITTSBURGH, March 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq:...
TNX-1500, a third generation anti-CD40L mAb, was Fc-modified to preserve the activity and bioavailability of first generation mAbs while addressing...
STOCKHOLM, SWEDEN / ACCESSWIRE / March 5, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
BERWYN, Pa.--(BUSINESS WIRE)--Amring Pharmaceuticals Inc. (“Amring”) announces its name change to Nordic Pharma, Inc. on March 4, 2024, following the...
ORLANDO, FL / ACCESSWIRE / March 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription...
Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for...
MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis...
Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase...
The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation...
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD...
Bobcat mRNATM technology is a novel linear mRNA platform able to encode large proteins Data showed restoration of muscular function...
WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces the formation...
Ethics and regulatory approvals finalized for world-first take-home use of a psychedelic medicine MB22001 in placebo-controlled trial in depressed patients...
Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
PALO ALTO, Calif., March 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused...
CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical...
VANCOUVER, BC / ACCESSWIRE / March 1, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to...